| Stockholders’ Equity |
Note
3 – Stockholders’ Equity
Common
Stock
During
the nine months ended September 30, 2025, we issued the following shares of common stock:
| |
● |
On
January 29, 2025, we sold 1,030,972 shares of our common stock, pre-funded warrants to purchase up to 7,019,700 shares of our common
stock, and accompanying Series A Warrants to purchase up to 8,050,672 shares of our common stock and Series B Warrants to purchase
up to 4,025,336 shares of our common stock for net proceeds of $4.4 million, after deducting placement agent fees and offering-related
expenses under a best efforts public offering (the “January offering”) at
a combined purchase price of $0.615 for institutional investors and $0.7975 for the Company’s Chief Executive Officer and certain
board members who participated in the offering. The Series A and B Warrants both have an exercise price of $0.65 per share of common
stock, and were subject to stockholder approval, which was obtained at our annual stockholder meeting on July 18, 2025. The Series
A Warrants will expire on July 18, 2030 and the Series B Warrants will expire on January 18, 2027. At September 30, 2025, all pre-funded
warrants sold in this offering were exercised;
|
| |
|
|
| |
● |
On
June 18, 2025, we sold 14,310,000 shares of our common stock, pre-funded warrants to purchase up to 13,690,000 shares of our common
stock. and accompanying common warrants to purchase up to 28,000,000 shares of our common stock for net proceeds of $6.2 million,
after deducting placement agent fees and offering-related expenses under a best efforts public offering (the “June offering”).
We sold one share of our common stock and accompanying common warrant at a combined price of $0.25 per share, and a pre-funded warrant
and accompanying common warrant at a combined price of $0.2499 per share. The common warrants have an exercise price of $0.25 per
share, are immediately exercisable and expire five years after their original issuance. The pre-funded warrants have an exercise
price of $0.0001 and are also immediately exercisable. We issued placement agent warrants to purchase up to 1,120,000 shares of common
stock at an exercise price of $0.31 per share. Warrants to purchase 2,912,422 shares of common stock for $728,000 and all pre-funded
warrants were exercised during the nine months ended September 30, 2025; |
| |
|
|
| |
● |
On
August 4, 2025, we sold 5,467,181 shares of our common stock at an offering price of $0.23 per share to an accredited investor for
net proceeds of $1.2 million, after deducting transaction-related expenses. We also sold 4,597,612 shares of our common stock for
net proceeds of $1.0 million under our ATM agreement; |
| |
|
|
| |
● |
76,189
shares of common stock to employees, net of 23,768 shares of common stock withheld for income and FICA taxes owed upon the distribution
of the shares; and |
| |
|
|
| |
● |
56,252
shares of common stock in connection with consulting agreements. |
As
of November 3, 2025, warrants to purchase an additional 3,781,267
of common stock were exercised for approximately $945,000.
|